Indication intelligence, analysis and sector perception

Pluristem (PSTI) proposes 4.76 M Registered Direct Offering (RDO) priced at $6.30

February 2, 2021 12:52pm

PSTI is trading down-$1.0 or -13.94% to $6.42

A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.

PSTI has entered into definitive agreements with institutional investors for the purchase and sale of 4,761,905 shares of its common stock at a purchase price of $6.30 per share in a registered direct offering.

Gross proceeds of $30 million before deducting placement agent fees and expenses.

The closing of the offering is expected to occur on or about February 4, 2021, subject to the satisfaction of customary closing conditions.

The Bottom line:

52-week change = +88.86$
52-week low of $2.82 and a high of $13.29
Shares outstanding: 25.63 M
Float: 18 M
Cash (as of last Q = $40.44
Total debt: $1.44 M

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 47 min ago
RegMed Investors (RMi) Closing Bell: I told you so

13 hours 35 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.